18 news items
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
URGN
17 Jun 24
), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced
UroGen Pharma Announced Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
URGN
17 Jun 24
to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has commenced an underwritten public
UroGen Pharma Announces Public Offering Of Ordinary Shares And Pre-Funded Warrants; No Size Or Amount Disclosed
URGN
17 Jun 24
to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has commenced an underwritten public
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
URGN
17 Jun 24
dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has commenced
UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
URGN
13 Jun 24
in the U.S. each year and may benefit from an innovative approach to treating their disease."
The most common
gkdg lp9m7t99w3
URGN
7 Jun 24
), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced
zw9k8e9xyws248g1umlqjzcfibqe0yi3w
URGN
5 Jun 24
), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced
f34j wrjedunf8w1x3gmw
URGN
22 May 24
), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced
tj4ox03 4o1ap9y
URGN
13 May 24
to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the first quarter
9volfd0gin2kfh9ef8dvzwwywvo8oaxo5yo2t6uq62 y5np
URGN
6 May 24
and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from a new analysis of the ATLAS trial, which
7zyfr51qie630d18w4wwnyta680foazmopum3zfabdj1xuhyhhysea7sfe
URGN
5 May 24
is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better
lzsq8wfdf tl9boprz
URGN
4 May 24
to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from a new analysis
dhdhn 1kp
URGN
4 May 24
administration and also underscore the significance of continuous research and innovation in elevating treatment standards for urothelial cancers
5m4ocfoih9yrql7wy8w4j3sq14c59g8du z9g
URGN
3 May 24
. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial
zfwovwb9zms tzsarol7i
URGN
17 Apr 24
. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial
wqg07ddi
URGN
VYGR
15 Apr 24
innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today
1s6cug8k
URGN
15 Apr 24
UGN-103UGN-103 (mitomycin) for intravesical solution is an innovative drug formulation of mitomycin being developed for the treatment
2ntj957i9ot uo58s
URGN
15 Apr 24
.
About UGN-103
UGN-103 (mitomycin) for intravesical solution is an innovative drug formulation
- Prev
- 1
- Next